challenges in visualizing pharmaceutical information ... · • competitive intelligence analyst...
TRANSCRIPT
Challenges in Visualizing Pharmaceutical Information – Smart Strategy Dashboards
Patents & IP Sequences | Clinical Trials | Drug Pipelines
www.bizint.com
IC-SDV 2018, Nice
Diane Q. Webb, President
23 April 2018
© 2018 BizInt Solutions, Inc | www.bizint.com 2
The Problem:
Visualizations developed for scientific and patent data do not do a good job of “telling the story” when applied to drug pipeline data and often need significant changes.
2013 II-SDV Paper: Challenges in Visualizing Pharmaceutical Business Information
© 2018 BizInt Solutions, Inc | www.bizint.com 3
The Drug Development “Pipeline”
At each stage of the pipeline, companies need information on drugs in development to make both business and research decisions.
© 2018 BizInt Solutions, Inc | www.bizint.com 4
Clinical Trials Phases in the Drug Pipeline
© 2018 BizInt Solutions, Inc | www.bizint.com 5
Source: Edi et al., Yang et al, Search Technology
Examples of Technical Visualizations
Found on the web
© 2018 BizInt Solutions, Inc | www.bizint.com 6
Source: Roche, Ligand, AmgenOncology websites
Examples of pharma pipeline visualizations
Found on the web
© 2018 BizInt Solutions, Inc | www.bizint.com 7
• Worked with a customer to automate the creation of labor intensive, hand-drawn product launch timelines.
• Result: Attractive computer-drawn visualizations…
• That required a lot of data preparation to create.
2016 II-SDV Paper: Competitive Launch Landscapes
More info: bizint.com/slides
© 2018 BizInt Solutions, Inc | www.bizint.com 8
• Decision maker who needs the visualization.• Competitive intelligence analyst who knows
the disease area and company interests.• Search specialist to collect the correct data.• Sophisticated tool user who can manipulate
the data.• In some companies, it can be hard to assemble
these skills.
Lessons Learned – You need a team
© 2018 BizInt Solutions, Inc | www.bizint.com 9
• Designed for analysts who don’t have the time to learn some or all of the BizInt tools.
• BizInt will use the BizInt Smart Charts tools to build BizInt Smart Strategy Dashboards for you.
• Smart Strategy Dashboards is a set of visualizations that address several questions about your topic:Who? What? Where? When?
BizInt Smart Strategy Dashboards (BizDash)
© 2018 BizInt Solutions, Inc | www.bizint.com 10
© 2018 BizInt Solutions, Inc | www.bizint.com 11
© 2018 BizInt Solutions, Inc | www.bizint.com 12
© 2018 BizInt Solutions, Inc | www.bizint.com 13
© 2018 BizInt Solutions, Inc | www.bizint.com 14
© 2018 BizInt Solutions, Inc | www.bizint.com 15
• There is some interest in an interactive visualization that people can explore…
• But the primary requirement is for a PowerPoint slide.
• An image in a PowerPoint slide is okay…• But you’d really like to create PowerPoint
objects (so you can customize the presentation and make final edits.)
Lessons Learned – It’s all about
© 2018 BizInt Solutions, Inc | www.bizint.com 16
Biological Testing
Merkel cell carcinoma therapiesVironika
Preclinical
CK-301TG Therapeutics
ETBX-051NantWorks
ETBX-061NantWorks
ipilimumabBristol-Myers Squibb Co
LTvaxAPCure
Merkel cell polyomavirus inhibitorsVironika
Phase I
BGB-A317Celgene
ID-G100Immune Design
pasireotideNovartis
SIRPa-FcTrillium Therapeutics
utomilumabPfizer
Phase II
ALT 803Altor BioScience Corporation
cabozantinib S-malateExelixis
CST-101NantWorks
F16-IL2Philogen
MCPyV vaccineFred Hutchinson Cancer Research Center
nivolumabOno Pharmaceutical Co Ltd
pazopanibGlaxoSmithKline plc
pembrolizumabMerck & Co
PEN-221Tarveda Therapeutics
sapanisertibIntellikine
talimogene laherparepvecBioVex Inc
tavokinogene telsaplasmidOncoSec Medical
Launched
avelumabMerck KGaA
Discontinued
lorvotuzumab mertansineImmunoGen
No Development Reported
ATN-161Attenuon
tivantinibArQule
Type of molecule
Antibody
Biological, other
Cell & gene therapy
Protein & peptide
Small molecule therapeutic
Vaccine
Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule
Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases.
Drugs color-coded by a chosen field
Labeled by drug name and a chosen field
Option for hyperlink to pipeline record
“Piano Chart” – PowerPoint visualization
Each column contains the drugs in that phase
© 2018 BizInt Solutions, Inc | www.bizint.com 17
Biological Testing
Merkel cell carcinoma therapiesVironika
Preclinical
CK-301TG Therapeutics
ETBX-051NantWorks
ETBX-061NantWorks
ipilimumabBristol-Myers Squibb Co
LTvaxAPCure
Merkel cell polyomavirus inhibitorsVironika
Phase I
BGB-A317Celgene
ID-G100Immune Design
pasireotideNovartis
SIRPa-FcTrillium Therapeutics
utomilumabPfizer
Phase II
ALT 803Altor BioScience Corporation
cabozantinib S-malateExelixis
CST-101NantWorks
F16-IL2Philogen
MCPyV vaccineFred Hutchinson Cancer Research Center
nivolumabOno Pharmaceutical Co Ltd
pazopanibGlaxoSmithKline plc
pembrolizumabMerck & Co
PEN-221Tarveda Therapeutics
sapanisertibIntellikine
talimogene laherparepvecBioVex Inc
tavokinogene telsaplasmidOncoSec Medical
Launched
avelumabMerck KGaA
Discontinued
lorvotuzumab mertansineImmunoGen
No Development Reported
ATN-161Attenuon
tivantinibArQule
Type of molecule
Antibody
Biological, other
Cell & gene therapy
Protein & peptide
Small molecule therapeutic
Vaccine
Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule
Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases.
Annotating the Piano Chart in PowerPoint
Key Competitor
Add box outlines to indicate Key Competitors
© 2018 BizInt Solutions, Inc | www.bizint.com 18
Biological Testing
Merkel cell carcinoma therapiesVironika
Preclinical
CK-301TG Therapeutics
ETBX-051NantWorks
ETBX-061NantWorks
ipilimumabBristol-Myers Squibb Co
LTvaxAPCure
Merkel cell polyomavirus inhibitorsVironika
Phase I
BGB-A317Celgene
ID-G100Immune Design
pasireotideNovartis
SIRPa-FcTrillium Therapeutics
utomilumabPfizer
Phase II
ALT 803Altor BioScience Corporation
cabozantinib S-malateExelixis
CST-101NantWorks
F16-IL2Philogen
MCPyV vaccineFred Hutchinson Cancer Research Center
nivolumabOno Pharmaceutical Co Ltd
pazopanibGlaxoSmithKline plc
pembrolizumabMerck & Co
PEN-221Tarveda Therapeutics
sapanisertibIntellikine
talimogene laherparepvecBioVex Inc
tavokinogene telsaplasmidOncoSec Medical
Launched
avelumabMerck KGaA
Discontinued
lorvotuzumab mertansineImmunoGen
No Development Reported
ATN-161Attenuon
tivantinibArQule
Type of molecule
Antibody
Biological, other
Cell & gene therapy
Protein & peptide
Small molecule therapeutic
Vaccine
Merkel cell carcinoma (MCC) pipeline: Phase for MCC and type of molecule
Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases.
Annotating the Piano Chart in PowerPoint
Key Competitor
Another way to indicate Key Competitors
© 2018 BizInt Solutions, Inc | www.bizint.com 19
• Everyone wants an “easy” button!• We’ve made the actual drawing of
the visualizations easy.• But a lot of data preparation is
necessary --
Lessons Learned – It’s not “Easy”
• Filter data to the most critical items (e.g. “Key Drugs”)
• Group values to create useful categories.• Shorten labels to fit.• Apply expertise for values not in the data.
© 2018 BizInt Solutions, Inc | www.bizint.com 20
Data Preparation for the Launch Timeline
Group items into a few categories Launch Date is
not a field in the data!
Group items into a few
colors.
© 2018 BizInt Solutions, Inc | www.bizint.com 21
Phase 1AEOL-10150AEOL-10150AEOL-10150allogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsARGX-110ARGX-110ARGX-110ARGX-110BGB-A317BGB-A317BGB-A317BGB-A317BGB-A317BGB-A317BGB-A317CB-839CB-839CB-839CK-301CK-301CK-301CK-301CK-301dasatinibdasatinibdasatinibdasatinibdasatinibFP-1039FP-1039FP-1039FP-1039FP-1039FP-1039gene therapyGL-ONC1GL-ONC1GL-ONC1GL-ONC1GL-ONC1imatinibimatinibimatinibimatinibimatinibimatinibLMB-100LMB-100LMB-100LMB-100LMB-100LY-3023414LY-3023414MesoCARTMesoCARTMesoCARTMesoCARTMesoCARTMesoCARTMesoCARTMTG-202MTG-202MTG-202MV-NISMV-NISMV-NISMV-NISMV-NIS therapyMV-NIS therapyMV-NIS therapyMV-NIS therapyMV-NIS therapyroniciclibroniciclibroniciclibtrametinibtrametinibtrametinibtrametinib
Phase 1/2JTCR-016JTCR-016JTCR-016JTCR-016JTCR-016pevonedistatpevonedistatpevonedistat
Phase 2aglatimagene besadenovecaglatimagene besadenovecaglatimagene besadenovecamatuximabamatuximabamatuximabamatuximabamatuximabamatuximabanti-mesothelin CAR engineered pbl therapyanti-mesothelin CAR engineered pbl therapyanti-mesothelin CAR engineered pbl therapyanti-mesothelin CAR engineered pbl therapyatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabAZD-4547AZD-4547AZD-4547AZD-4547BNC-105PBNC-105PBNC-105PBNC-105Pbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotincarfilzomibcarfilzomibcarfilzomibcarfilzomibcarfilzomibcarfilzomibCBP-501CBP-501CBP-501CRS-207CRS-207CRS-207CRS-207CRS-207defactinibdefactinibdefactinibdurvalumabdurvalumabdurvalumabdurvalumabdurvalumabdurvalumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabgalinpepimut-Sgalinpepimut-Sgalinpepimut-Sgalinpepimut-Sgalinpepimut-Sgemcitabine prodruggemcitabine prodruggemcitabine prodruggemcitabine prodruggemcitabine prodrugHSV-1716HSV-1716HSV-1716HSV-1716K562/GM-CSFK562/GM-CSFK562/GM-CSFK562/GM-CSFlurbinectedinlurbinectedinlurbinectedinMinervalMinervalMinervalmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsMTG-201MTG-201MTG-201napabucasinnapabucasinnapabucasinONCOS-102ONCOS-102ONCOS-102ONCOS-102pegargiminasepegargiminasepegargiminasepegargiminasepegargiminasepembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabporfimer sodiumporfimer sodiumSSSSSSSSSSsunitinibsunitinibsunitinibtazemetostattazemetostattrabectedintrabectedintrabectedintrabectedintrabectedintrabectedinTRC-102TRC-102TRC-102tremelimumabtremelimumabtremelimumabtremelimumabtremelimumabtremelimumabTroVaxTroVaxTroVaxTroVaxTroVaxvinorelbinevinorelbinevinorelbinevinorelbineWT1-targeted autologous dendritic cell vaccineWT1-targeted autologous dendritic cell vaccineWT1-targeted autologous dendritic cell vaccineWT1-targeted autologous dendritic cell vaccineYSCMAYSCMAYSCMAYSCMAYSCMAYSCMAzoledronic acidzoledronic acidzoledronic acidzoledronic acidzoledronic acid
Phase 3ipilimumabipilimumabipilimumabipilimumabipilimumabipilimumabipilimumabNGR-hTNFNGR-hTNFNGR-hTNFNGR-hTNFNGR-hTNFnintedanibnintedanibnintedanibnintedanibnivolumabnivolumabnivolumabnivolumabnivolumabnivolumabnivolumab
Preregistrationpemetrexedpemetrexedpemetrexed
LaunchedPemetrexed - CJ Healthcarepemetrexed disodiumpemetrexed disodiumpemetrexed disodiumpemetrexed disodiumpemetrexed disodiumraltitrexedraltitrexedraltitrexed
TechnologiesAntibodyAntibody conjugatedAntibody fragmentAntigenAntigen presentation systemBacteria recombinantBiological therapeuticCapsule formulationCell therapyChimeric antibodyChimeric antigen receptor T cell therapyChimeric monoclonal antibodyDrug combinationFilm coatingFormulation powderFreeze dryingImagingImmuno-oncologyImmunoglobulin-GInfusionInjectable formulationIntradermal formulationIntramuscular formulationIntraperitoneal formulationIntratumoral formulationIntravenous formulationLipidLiquid formulationLymphocyteMonoclonal antibodyNanoparticle formulation injectableNatural productNucleotide and derivativesOligonucleotideOral formulationParenteral formulation unspecifiedPEGylated formulationPeptideProdrugProtein conjugatedProtein fusionProtein recombinantReceptor chimericRecombinant enzymeSmall molecule therapeuticSolutionSubcutaneous formulationSystemic formulation unspecifiedT-lymphocyteTablet formulationToxin binding proteinTumor antigenTumor antigen therapeuticVirus recombinant
Piano Chart - Mesothelioma
Piano Chart without data preparation
This is horrible!
© 2018 BizInt Solutions, Inc | www.bizint.com 22
Piano Chart without data preparationPhase 1AEOL-10150AEOL-10150AEOL-10150allogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsallogeneic tumor lysate-pulsed autologous dendritic cellsARGX-110ARGX-110ARGX-110ARGX-110BGB-A317BGB-A317BGB-A317BGB-A317BGB-A317BGB-A317BGB-A317CB-839CB-839CB-839CK-301CK-301CK-301CK-301CK-301dasatinibdasatinibdasatinibdasatinibdasatinibFP-1039FP-1039FP-1039FP-1039FP-1039FP-1039gene therapyGL-ONC1GL-ONC1GL-ONC1GL-ONC1GL-ONC1imatinibimatinibimatinibimatinibimatinibimatinibLMB-100LMB-100LMB-100LMB-100LMB-100LY-3023414LY-3023414MesoCARTMesoCARTMesoCARTMesoCARTMesoCARTMesoCARTMesoCARTMTG-202MTG-202MTG-202MV-NISMV-NISMV-NISMV-NISMV-NIS therapyMV-NIS therapyMV-NIS therapyMV-NIS therapyMV-NIS therapyroniciclibroniciclibroniciclibtrametinibtrametinibtrametinibtrametinib
Phase 1/2JTCR-016JTCR-016JTCR-016JTCR-016JTCR-016pevonedistatpevonedistatpevonedistat
Phase 2aglatimagene besadenovecaglatimagene besadenovecaglatimagene besadenovecamatuximabamatuximabamatuximabamatuximabamatuximabamatuximabanti-mesothelin CAR engineered pbl therapyanti-mesothelin CAR engineered pbl therapyanti-mesothelin CAR engineered pbl therapyanti-mesothelin CAR engineered pbl therapyatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabatezolizumabAZD-4547AZD-4547AZD-4547AZD-4547BNC-105PBNC-105PBNC-105PBNC-105Pbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotinbrentuximab vedotincarfilzomibcarfilzomibcarfilzomibcarfilzomibcarfilzomibcarfilzomibCBP-501CBP-501CBP-501CRS-207CRS-207CRS-207CRS-207CRS-207defactinibdefactinibdefactinibdurvalumabdurvalumabdurvalumabdurvalumabdurvalumabdurvalumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabdurvalumab + tremelimumabgalinpepimut-Sgalinpepimut-Sgalinpepimut-Sgalinpepimut-Sgalinpepimut-Sgemcitabine prodruggemcitabine prodruggemcitabine prodruggemcitabine prodruggemcitabine prodrugHSV-1716HSV-1716HSV-1716HSV-1716K562/GM-CSFK562/GM-CSFK562/GM-CSFK562/GM-CSFlurbinectedinlurbinectedinlurbinectedinMinervalMinervalMinervalmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsmiR-15/16 mimicsMTG-201MTG-201MTG-201napabucasinnapabucasinnapabucasinONCOS-102ONCOS-102ONCOS-102ONCOS-102pegargiminasepegargiminasepegargiminasepegargiminasepegargiminasepembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabpembrolizumabporfimer sodiumporfimer sodiumSSSSSSSSSSsunitinibsunitinibsunitinibtazemetostattazemetostattrabectedintrabectedintrabectedintrabectedintrabectedintrabectedinTRC-102TRC-102TRC-102tremelimumabtremelimumabtremelimumabtremelimumabtremelimumabtremelimumabTroVaxTroVaxTroVaxTroVaxTroVaxvinorelbinevinorelbinevinorelbinevinorelbineWT1-targeted autologous dendritic cell vaccineWT1-targeted autologous dendritic cell vaccineWT1-targeted autologous dendritic cell vaccineWT1-targeted autologous dendritic cell vaccineYSCMAYSCMAYSCMAYSCMAYSCMAYSCMAzoledronic acidzoledronic acidzoledronic acidzoledronic acidzoledronic acid
Phase 3ipilimumabipilimumabipilimumabipilimumabipilimumabipilimumabipilimumabNGR-hTNFNGR-hTNFNGR-hTNFNGR-hTNFNGR-hTNFnintedanibnintedanibnintedanibnintedanibnivolumabnivolumabnivolumabnivolumabnivolumabnivolumabnivolumab
Preregistrationpemetrexedpemetrexedpemetrexed
LaunchedPemetrexed - CJ Healthcarepemetrexed disodiumpemetrexed disodiumpemetrexed disodiumpemetrexed disodiumpemetrexed disodiumraltitrexedraltitrexedraltitrexed
TechnologiesAntibodyAntibody conjugatedAntibody fragmentAntigenAntigen presentation systemBacteria recombinantBiological therapeuticCapsule formulationCell therapyChimeric antibodyChimeric antigen receptor T cell therapyChimeric monoclonal antibodyDrug combinationFilm coatingFormulation powderFreeze dryingImagingImmuno-oncologyImmunoglobulin-GInfusionInjectable formulationIntradermal formulationIntramuscular formulationIntraperitoneal formulationIntratumoral formulationIntravenous formulationLipidLiquid formulationLymphocyteMonoclonal antibodyNanoparticle formulation injectableNatural productNucleotide and derivativesOligonucleotideOral formulationParenteral formulation unspecifiedPEGylated formulationPeptideProdrugProtein conjugatedProtein fusionProtein recombinantReceptor chimericRecombinant enzymeSmall molecule therapeuticSolutionSubcutaneous formulationSystemic formulation unspecifiedT-lymphocyteTablet formulationToxin binding proteinTumor antigenTumor antigen therapeuticVirus recombinant
Piano Chart - Mesothelioma
TechnologiesAntibody
Antibody conjugated
Antibody fragment
Antigen
Antigen presentation
Bacteria recombinant
Biological therapeutic
Capsule formulation
Cell therapy
Need to refine Technologies for a more effective key
© 2018 BizInt Solutions, Inc | www.bizint.com 23
Phase I
AEOL-10150
ARGX-110
BGB-A317
CB-839
CK-301
dasatinib
FP-1039
gene therapy
GL-ONC1
imatinib
LMB-100
LY-3023414
MesoCART
MesoPher
MTG-202
MV-NIS
MV-NIS therapy
roniciclib
trametinib
Phase I/II
JTCR-016
pevonedistat
Phase II
aglatimagene besadenovec
amatuximab
anti-mesothelin CAR
atezolizumab
AZD-4547
BNC-105P
brentuximab vedotin
carfilzomib
CAT-5001
CBP-501
CRS-207
defactinib
durvalumab
durvalumab + tremelimumab
galinpepimut-S
gemcitabine prodrug
HSV-1716
K562/GM-CSF
lurbinectedin
Minerval
miR-15/16 mimics
MTG-201
napabucasin
ONCOS-102
pegargiminase
pembrolizumab
porfimer sodium
sunitinib
tazemetostat
trabectedin
TRC-102
tremelimumab
TroVax
vinorelbine
WT1-targeted vaccine
YSCMA
zoledronic acid
Phase III
ipilimumab
NGR-hTNF
nintedanib
nivolumab
Launched
pemetrexed
raltitrexed
Drug typeAntibodies
Cancer-vaccines
Cell/Gene therapies
Oncolytic viruses
Peptides/Proteins
Small molecules
Piano Chart Mesothelioma
Piano Chart – creating a useful color key
Grouping Technology terms into Drug Types creates a useful key
© 2018 BizInt Solutions, Inc | www.bizint.com 24
Phase 1
AEOL-10150ARGX-110
BGB-A317
CB-839
CK-301
dasatinib
FP-1039
gene therapy
GL-ONC1
imatinib
LMB-100
LY-3023414
MesoCART
MesoPher
MTG-202
MV-NIS
MV-NIS therapy
roniciclib
trametinib
Phase 1/2
JTCR-016
pevonedistat
Phase 2
aglatimagene besadenovecamatuximab
anti-mesothelin CAR
atezolizumab
AZD-4547
BNC-105P
brentuximab vedotin
carfilzomib
CAT-5001
CBP-501
CRS-207
defactinib
durvalumab
durvalumab + tremelimumabgalinpepimut-S
gemcitabine prodrug
HSV-1716
K562/GM-CSF
Phase 2
lurbinectedin
Minerval
miR-15/16 mimics
MTG-201
napabucasin
ONCOS-102
pegargiminase
pembrolizumab
porfimer sodium
sunitinib
tazemetostat
trabectedin
TRC-102
tremelimumab
TroVax
vinorelbine
WT1-targeted vaccine
YSCMA
zoledronic acid
Phase 3
ipilimumab
NGR-hTNF
nintedanib
nivolumab
Launched
pemetrexed
raltitrexed
Drug typeAntibodies
Cancer vaccines
Cell/Gene therapies
Oncolytic viruses
Peptides/Proteins
Small molecules
Piano Chart – Mesothelioma
Piano Chart – how to display large columns
Display Phase 2 drugs in two columns
© 2018 BizInt Solutions, Inc | www.bizint.com 25
• Color code key should have no more than 8 colors; 5-6 is better.
• For key values with a progression (e.g. phase, trial status) choose a sequential color scheme.
• For key values with no order (e.g. companies) choose a qualitativecolor scheme.
Lessons Learned – Choose the Right Colors
© 2018 BizInt Solutions, Inc | www.bizint.com 26
Biological Testing
Merkel cell carcinoma therapiesVironika
Preclinical
CK-301TG Therapeutics
ETBX-051NantWorks
ETBX-061NantWorks
ipilimumabBristol-Myers Squibb Co
LTvaxAPCure
Merkel cell polyomavirus inhibitorsVironika
Phase I
BGB-A317Celgene
ID-G100Immune Design
pasireotideNovartis
SIRPa-FcTrillium Therapeutics
utomilumabPfizer
Phase II
ALT 803Altor BioScience Corporation
cabozantinib S-malateExelixis
CST-101NantWorks
F16-IL2Philogen
MCPyV vaccineFred Hutchinson Cancer Research Center
nivolumabOno Pharmaceutical Co Ltd
pazopanibGlaxoSmithKline plc
pembrolizumabMerck & Co
PEN-221Tarveda Therapeutics
sapanisertibIntellikine
talimogene laherparepvecBioVex Inc
tavokinogene telsaplasmidOncoSec Medical
Launched
avelumabMerck KGaA
Discontinued
lorvotuzumab mertansineImmunoGen
No Development Reported
ATN-161Attenuon
tivantinibArQule
Type of molecule
Antibody
Biological, other
Cell & gene therapy
Protein & peptide
Small molecule therapeutic
Vaccine
Merkel cell carcinoma (MCC) pipeline: by Type of Molecule
Background: Data from Pharmaprojects, R&D Insight, Cortellis was integrated in BizInt Smart Charts, cleaned up and visualized with VP-SCE. Phase for MCC was extracted from the Drug Development Phase field. Values shown are those reported by the databases.
Piano chart: Qualitative Color Code Key
© 2018 BizInt Solutions, Inc | www.bizint.com 27
Merkel cell carcinoma (MCC) trials: by Trial Status
Piano chart: Sequential Color Code Key
© 2018 BizInt Solutions, Inc | www.bizint.com 28
• The one that “tells the story” for your topic and data.
• Try different visualizations and different categorizations/color code keys.
• A visualization that works well for one data set might not be very interesting for your next project.
Lessons Learned – The Best Visualization is…
Phase I Phase I/II Phase II
aglatimagene besadenovec
amatuximab
anti-mesothelin CAR
atezolizumab
AZD-4547
BNC-105P
brentuximab vedotin
carfilzomib
CAT-5001
CBP-501
CRS-207
defactinib
durvalumab
durvalumab + tremelimumab
galinpepimut-S
gemcitabine prodrug
HSV-1716
K562/GM-CSF
lurbinectedin
Minerval
miR-15/16 mimics
MTG-201
napabucasin
ONCOS-102
pegargiminase
pembrolizumab
porfimer sodium
sunitinib
tazemetostat
trabectedin
TRC-102
tremelimumab
TroVax
vinorelbine
WT1-targeted vaccine
YSCMA
zoledronic acid
Phase III Launched
© 2018 BizInt Solutions, Inc | www.bizint.com 29
Sample “bulls-eye” charts - 2013 II-SDV Paper –
Found on the web
© 2018 BizInt Solutions, Inc | www.bizint.com 30
Phase 1
AEOL-10150ARGX-110
BGB-A317
CB-839
CK-301
dasatinib
FP-1039
gene therapy
GL-ONC1
imatinib
LMB-100
LY-3023414
MesoCART
MesoPher
MTG-202
MV-NIS
MV-NIS therapy
roniciclib
trametinib
Phase 1/2
JTCR-016
pevonedistat
Phase 2
aglatimagene besadenovecamatuximab
anti-mesothelin CAR
atezolizumab
AZD-4547
BNC-105P
brentuximab vedotin
carfilzomib
CAT-5001
CBP-501
CRS-207
defactinib
durvalumab
durvalumab + tremelimumabgalinpepimut-S
gemcitabine prodrug
HSV-1716
K562/GM-CSF
Phase 2
lurbinectedin
Minerval
miR-15/16 mimics
MTG-201
napabucasin
ONCOS-102
pegargiminase
pembrolizumab
porfimer sodium
sunitinib
tazemetostat
trabectedin
TRC-102
tremelimumab
TroVax
vinorelbine
WT1-targeted vaccine
YSCMA
zoledronic acid
Phase 3
ipilimumab
NGR-hTNF
nintedanib
nivolumab
Launched
pemetrexed
raltitrexed
Drug typeAntibodies
Cancer vaccines
Cell/Gene therapies
Oncolytic viruses
Peptides/Proteins
Small molecules
Piano Chart – Mesothelioma
Mesothelioma pipeline in a Piano Chart
Would a bulls-eye be better for this dataset?
© 2018 BizInt Solutions, Inc | www.bizint.com 31
amatuximab
ARGX-110atezolizumab
BGB-A317brentuximab vedotin
CAT-5001
CK-301
durvalumabdurvalumab + tremelimumab
ipilimumab
nivolumab
pembrolizumabtremelimumab
YSCMA
CRS-207galinpepimut-S
JTCR-016
K562/GM-CSF
MesoPher
TroVaxWT1 vaccine
aglatimagene besadenovec
anti-mesothelin CAR
gene therapy
MesoCART
miR-15/16 mimicsMTG-201
MTG-202
GL-ONC1
HSV-1716MV-NIS
MV-NIS therapy
ONCOS-102
CBP-501
FP-1039
LMB-100
NGR-hTNF
pegargiminase
AEOL-10150AZD-4547
BNC-105Pcarfilzomib
CB-839dasatinib
defactinibgemcitabine prodrug
imatinib
lurbinectedin
LY-3023414
Minervalnapabucasin
nintedanib
pemetrexed
pevonedistat
porfimer sodium
raltitrexed
roniciclib
sunitinib
tazemetostattrabectedin
trametinib
TRC-102vinorelbine
zoledronic acid
Small molecules
Cell/Gene therapies
Antibodies
Peptides/Proteins
Cancer vaccines
Oncolytic viruses
Mesothelioma – Bulls-Eye created for PowerPoint
Marketed
Phase 3
Phase 2
Phase 1
Now part of:
Thank you to my “chef” colleagues
at BizInt and VantagePoint!
Matt EberleJohn Willmore, Joe Johnson, Bertha Adamson and Jon Garner, Paul Frey, Nils Newman
